GRAIL, LLC: GRAIL and University of Oxford to Present Results From First Prospective Study of Multi-Cancer Early Detection in a Symptomatic Patient Population at 2023 ASCO Annual Meeting
SYMPLIFY Results Demonstrate Strong Performance of GRAIL's Multi-Cancer Early Detection Methylation-Based Platform in Individuals Presenting With Non-Specific Signs and Symptoms Results in Press
Source: finanznachrichten.de